You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2024

CLINICAL TRIALS PROFILE FOR DROSPIRENONE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for drospirenone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00102141 ↗ Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women Completed Bayer Phase 3 2004-04-01 The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension.
NCT00185419 ↗ A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception Completed Bayer Phase 3 2003-11-01 The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in healthy Chinese women
NCT00185484 ↗ Efficacy and Safety Oral Contraceptive Study Completed Bayer Phase 3 2004-03-01 The purpose of this study is to determine whether the study drug is effective in prevention of pregnancy in healthy women in reproductive age
NCT00266032 ↗ Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles Completed Bayer Phase 3 2005-12-01 The purpose of the study is to determine safety and efficacy of long-cycle regimens of an oral contraceptive.
NCT00302848 ↗ European Active Surveillance Study (EURAS) Completed Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma 2000-11-01 EURAS is a multi-national, controlled, prospective, post-marketing, non-intervention cohort study of new users of drospirenone/ethinylestradiol (DRSP/EE), levonorgestrel/ethinylestradiol (LNG/EE) and other oral contraceptives (OCs) under routine conditions of medical practice in seven European countries. Baseline survey and semiannual, active follow-up are based on postal questionnaires, with validation of reported events by the women's treating physicians. A multifaceted 4-level follow-up procedure will be established to ensure low loss to follow-up rates. The objective of the study is the investigation of the incidence of rare serious adverse events associated with the use of new and established OCs, and specifically the incidence of thromboembolic events.
NCT00302848 ↗ European Active Surveillance Study (EURAS) Completed Center for Epidemiology and Health Research, Germany 2000-11-01 EURAS is a multi-national, controlled, prospective, post-marketing, non-intervention cohort study of new users of drospirenone/ethinylestradiol (DRSP/EE), levonorgestrel/ethinylestradiol (LNG/EE) and other oral contraceptives (OCs) under routine conditions of medical practice in seven European countries. Baseline survey and semiannual, active follow-up are based on postal questionnaires, with validation of reported events by the women's treating physicians. A multifaceted 4-level follow-up procedure will be established to ensure low loss to follow-up rates. The objective of the study is the investigation of the incidence of rare serious adverse events associated with the use of new and established OCs, and specifically the incidence of thromboembolic events.
NCT00356447 ↗ Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. Completed Bayer Phase 3 2006-05-01 The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro-genital complaints.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for drospirenone

Condition Name

Condition Name for drospirenone
Intervention Trials
Contraception 32
Polycystic Ovary Syndrome 12
Healthy 9
Premenstrual Syndrome 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for drospirenone
Intervention Trials
Polycystic Ovary Syndrome 14
Syndrome 14
Dysmenorrhea 7
Endometriosis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for drospirenone

Trials by Country

Trials by Country for drospirenone
Location Trials
United States 169
China 50
Germany 48
Japan 40
United Kingdom 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for drospirenone
Location Trials
Pennsylvania 11
Florida 10
California 10
Texas 8
Arizona 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for drospirenone

Clinical Trial Phase

Clinical Trial Phase for drospirenone
Clinical Trial Phase Trials
Phase 4 22
Phase 3 40
Phase 2/Phase 3 3
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for drospirenone
Clinical Trial Phase Trials
Completed 72
Unknown status 11
Not yet recruiting 6
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for drospirenone

Sponsor Name

Sponsor Name for drospirenone
Sponsor Trials
Bayer 39
Estetra 9
Massachusetts General Hospital 3
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for drospirenone
Sponsor Trials
Industry 78
Other 44
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.